21 U.S.C. § 360bbb–5
Critical Path Public-Private Partnerships
Exact citation match for 21 USC § 360BBB-5
Search
Search by citation or keyword across the current edition within Title 21.
Critical Path Public-Private Partnerships
Exact citation match for 21 USC § 360BBB-5
Activities of the Food and Drug Administration
Activities of the Food and Drug Administration
Patient participation in medical product discussion
Patient participation in medical product discussion
Expanded access to unapproved therapies and diagnostics
Expanded access to unapproved therapies and diagnostics
Expanded access policy required for investigational drugs
Expanded access policy required for investigational drugs
Countermeasure development, review, and technical assistance
Countermeasure development, review, and technical assistance
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
Notification, nondistribution, and recall of controlled substances
Notification, nondistribution, and recall of controlled substances
Authorization for medical products for use in emergencies
Authorization for medical products for use in emergencies
Priority review to encourage treatments for agents that present national security threats
Priority review to encourage treatments for agents that present national security threats
Discontinuance or interruption in the production of medical devices
Discontinuance or interruption in the production of medical devices